{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:26:04Z","timestamp":1790270764075,"version":"4.1.0"},"reference-count":63,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:p>Dry eye disease encompasses a broad range of etiologies and disease subtypes which have similar clinical manifestations. Medications can cause dry eye disease or symptoms of dryness as a side effect by either interfering with the lacrimal gland or meibomian gland function, or both, and by other mechanisms that affect the ocular surface homeostasis. This is important to know and recognize as eliminating the offending medication can reverse the symptoms and, in many cases, prevent further deterioration of the ocular surface inflammation. This review focuses on drugs like systemic isotretinoin and taxanes, which cause meibomian gland dysfunction; immune checkpoint inhibitors that cause lacrimal gland dysfunction; gliptins and topical antiglaucoma medications that cause cicatrizing conjunctivitis; and epidermal growth factor receptor inhibitors, fibroblast growth factor receptor inhibitors, and belantamab mafodotin, which cause mucosal epitheliopathy. Many of these medications, particularly the newer anticancer agents, have only recently been introduced for clinical use, and knowledge and awareness of their ocular side effects are still evolving. This review aims to update ophthalmologists on the drug-induced causes of dry eye disease or symptoms of dryness, which is avoidable by discontinuation of the incriminating agent or can be mitigated by reducing the dose or frequency of usage.<\/jats:p>","DOI":"10.4103\/ijo.ijo_2782_22","type":"journal-article","created":{"date-parts":[[2023,4,8]],"date-time":"2023-04-08T11:10:52Z","timestamp":1680952252000},"page":"1263-1269","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":35,"title":["A review on drug-induced dry eye disease"],"prefix":"10.4103","volume":"71","author":[{"given":"Ka Wai","family":"Kam","sequence":"first","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong SAR, China"},{"name":"Department of Ophthalmology and Visual Sciences, Prince of Wales Hospital, Hong Kong SAR, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Di Zazzo","sequence":"additional","affiliation":[{"name":"Ophthalmology Unit, Campus Bio Medico Foundation University Hospital, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"De Gregorio","sequence":"additional","affiliation":[{"name":"Ophthalmology Unit, Campus Bio Medico Foundation University Hospital, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Purvasha","family":"Narang","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, All India Institute of Medical Sciences, Nagpur, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishal","family":"Jhanji","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, UPMC Eye Center, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayan","family":"Basu","sequence":"additional","affiliation":[{"name":"The Cornea Institute, LV Prasad Eye Institute, Hyderabad, Telangana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,4,5]]},"reference":[{"key":"R1-20240828","doi-asserted-by":"crossref","first-page":"285851","DOI":"10.1155\/2012\/285851","article-title":"The role of medications in causing dry eye","volume":"2012","author":"Fraunfelder","year":"2012","journal-title":"J Ophthalmol"},{"key":"R2-20240828","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.jtos.2017.05.004","article-title":"TFOS DEWS II iatrogenic report","volume":"15","author":"Gomes","year":"2017","journal-title":"Ocul Surf"},{"key":"R3-20240828","first-page":"1559","article-title":"Pathogenesis of blepharoconjunctivitis complicating 13-cis-retinoic acid (isotretinoin) therapy in a laboratory model","volume":"29","author":"Lambert","year":"1988","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R4-20240828","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/1523-1747.ep12277122","article-title":"Effects of 13-cis-retinoic acid on the hamster meibomian gland","volume":"92","author":"Lambert","year":"1989","journal-title":"J Invest Dermatol"},{"key":"R5-20240828","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1159\/000267402","article-title":"Toxic effects of systemic retinoids on meibomian glands","volume":"26","author":"Kremer","year":"1994","journal-title":"Ophthalmic Res"},{"key":"R6-20240828","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/S0161-6420(79)35468-9","article-title":"Blepharoconjunctivitis:a side effect of 13-cis-retinoic acid therapy for dermatologic diseases","volume":"86","author":"Blackman","year":"1979","journal-title":"Ophthalmology"},{"key":"R7-20240828","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/0002-9394(85)90676-2","article-title":"Adverse ocular reactions possibly associated with isotretinoin","volume":"100","author":"Fraunfelder","year":"1985","journal-title":"Am J Ophthalmol"},{"key":"R8-20240828","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/00003226-199107000-00002","article-title":"Meibomian gland morphology and tear osmolarity:changes with Accutane therapy","volume":"10","author":"Mathers","year":"1991","journal-title":"Cornea"},{"key":"R9-20240828","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1177\/112067210201200316","article-title":"Lacrimal function and ocular complications in patients treated with systemic isotretinoin","volume":"12","author":"Bozkurt","year":"2002","journal-title":"Eur J Ophthalmol"},{"key":"R10-20240828","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s10792-016-0263-y","article-title":"Reduced ocular surface disease index (OSDI) scores in patients with isotretinoin treatment","volume":"37","author":"Caglar","year":"2017","journal-title":"Int Ophthalmol"},{"key":"R11-20240828","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1080\/09546634.2020.1774041","article-title":"The effect of oral isotretinoin therapy on meibomian gland morphology and dry eye tests","volume":"33","author":"Duzgun","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"R12-20240828","first-page":"11206721211018361","article-title":"Longitudinal assessment of meibomian glands and tear film layer in systemic isotretinoin treatment","author":"Tanriverdi","year":"2021","journal-title":"Eur J Ophthalmol"},{"key":"R13-20240828","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1007\/s10792-021-02205-1","article-title":"The effect of isotretinoin on meibomian glands in eyes:a pilot study","volume":"42","author":"Gurlevik","year":"2022","journal-title":"Int Ophthalmol"},{"key":"R14-20240828","first-page":"559","article-title":"The role of transcription factor FoxO1 in the pathogenesis of acne vulgaris and the mode of isotretinoin action","volume":"145","author":"Melnik","year":"2010","journal-title":"G Ital Dermatol Venereol"},{"key":"R15-20240828","doi-asserted-by":"crossref","first-page":"141","DOI":"10.4161\/derm.15331","article-title":"Isotretinoin and FoxO1:A scientific hypothesis","volume":"3","author":"Melnik","year":"2011","journal-title":"Dermatoendocrinol"},{"key":"R16-20240828","doi-asserted-by":"crossref","DOI":"10.5935\/0004-2749.20230025","article-title":"Assessments of the ocular surface and meibomian gland morphology in patients with treatment-I acne vulgaris","author":"Koca","year":"2022","journal-title":"Arq Bras Oftalmol"},{"key":"R17-20240828","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/sj.pcan.4500939","article-title":"Docetaxel-induced meibomian duct inflammation and blockage leading to chalazion formation","volume":"10","author":"Gupta","year":"2007","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"R18-20240828","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1177\/1120672120969045","article-title":"Ophthalmic adverse effects of taxanes:The Mayo Clinic experience","volume":"32","author":"Fortes","year":"2022","journal-title":"Eur J Ophthalmol"},{"key":"R19-20240828","first-page":"XE01","article-title":"Current development of anti-cancer drug S-1","volume":"10","author":"Chhetri","year":"2016","journal-title":"J Clin Diagn Res"},{"key":"R20-20240828","doi-asserted-by":"crossref","first-page":"1275.e4","DOI":"10.1016\/j.ophtha.2010.01.048","article-title":"S-1 induces meibomian gland dysfunction","volume":"117","author":"Matsumoto","year":"2010","journal-title":"Ophthalmology"},{"key":"R21-20240828","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/j.1442-9071.2012.02865.x","article-title":"Dry eye syndrome in aromatase inhibitor users","volume":"41","author":"Turaka","year":"2013","journal-title":"Clin Exp Ophthalmol"},{"key":"R22-20240828","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/tbj.12633","article-title":"Ocular surface disease in breast cancer patients using aromatase inhibitors","volume":"22","author":"Chatziralli","year":"2016","journal-title":"Breast J"},{"key":"R23-20240828","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jtos.2019.10.008","article-title":"Dry eye signs and symptoms in aromatase inhibitor treatment and the relationship with pain","volume":"18","author":"Gibson","year":"2020","journal-title":"Ocul Surf"},{"key":"R24-20240828","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1038\/s41433-021-01538-6","article-title":"Dry eye signs and symptoms in patients on aromatase inhibitor therapy","volume":"36","author":"Khoo","year":"2022","journal-title":"Eye (Lond)"},{"key":"R25-20240828","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1038\/s41433-021-01612-z","article-title":"The effects of systemic aromatase inhibitors on meibomian glands and corneal structure","volume":"36","author":"Agin","year":"2022","journal-title":"Eye (Lond)"},{"key":"R26-20240828","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1080\/07357907.2021.1971241","article-title":"Nivolumab-related dry mouth and dry eye:Cross-sectional study","volume":"39","author":"Yildirim","year":"2021","journal-title":"Cancer Invest"},{"key":"R27-20240828","doi-asserted-by":"crossref","first-page":"420","DOI":"10.3389\/fonc.2020.00420","article-title":"Lack of conventional acinar cells in parotid salivary gland of patient taking an anti-PD-L1 immune checkpoint inhibitor","volume":"10","author":"Pringle","year":"2020","journal-title":"Front Oncol"},{"key":"R28-20240828","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1080\/09273948.2019.1583347","article-title":"Ocular adverse events following use of immune checkpoint inhibitors for metastatic malignancies","volume":"28","author":"Noble","year":"2020","journal-title":"Ocul Immunol Inflamm"},{"key":"R29-20240828","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1111\/odi.14000","article-title":"Sicca syndrome associated with immune checkpoint inhibitor therapy","volume":"28","author":"Harris","year":"2022","journal-title":"Oral Dis"},{"key":"R30-20240828","doi-asserted-by":"crossref","first-page":"e65","DOI":"10.1016\/S1470-2045(18)30520-5","article-title":"Tyrosine kinase inhibitor-induced corneal ulcers","volume":"20","author":"Kam","year":"2019","journal-title":"Lancet Oncol"},{"key":"R31-20240828","doi-asserted-by":"crossref","first-page":"614","DOI":"10.3390\/cells8060614","article-title":"Fibroblast growth factor receptors (FGFRs):Structures and small molecule inhibitors","volume":"8","author":"Dai","year":"2019","journal-title":"Cells"},{"key":"R32-20240828","doi-asserted-by":"crossref","first-page":"100818","DOI":"10.1016\/j.ajoc.2020.100818","article-title":"Trichiasis and dry eye syndrome in two patients on novel fibroblast growth factor receptor inhibitor therapies","volume":"19","author":"Vinson","year":"2020","journal-title":"Am J Ophthalmol Case Rep"},{"key":"R33-20240828","doi-asserted-by":"crossref","first-page":"5366","DOI":"10.1158\/1078-0432.CCR-17-0645","article-title":"A Phase Ib open-label multicenter study of AZD4547 in patients with advanced squamous cell lung cancers","volume":"23","author":"Paik","year":"2017","journal-title":"Clin Cancer Res"},{"key":"R34-20240828","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.annonc.2022.02.001","article-title":"FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF\/FGFR alterations and advanced malignancies","volume":"33","author":"Subbiah","year":"2022","journal-title":"Ann Oncol"},{"key":"R35-20240828","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","article-title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2):A two-arm, randomised, open-label, phase 2 study","volume":"21","author":"Lonial","year":"2020","journal-title":"Lancet Oncol"},{"key":"R36-20240828","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s40123-020-00280-8","article-title":"Corneal epithelial findings in patients with multiple myeloma treated with antibody-drug conjugate belantamab mafodotin in the pivotal, randomized, DREAMM-2 study","volume":"9","author":"Farooq","year":"2020","journal-title":"Ophthalmol Ther"},{"key":"R37-20240828","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/s41408-021-00494-4","article-title":"Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM)","volume":"11","author":"Lonial","year":"2021","journal-title":"Blood Cancer J"},{"key":"R38-20240828","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jtos.2022.07.004","article-title":"Drug-induced pemphigoid:Clinical presentation, diagnosis, and management of gliptin-associated cicatrizing conjunctivitis","volume":"26","author":"Kate","year":"2022","journal-title":"Ocul Surf"},{"key":"R39-20240828","doi-asserted-by":"crossref","first-page":"101528","DOI":"10.1016\/j.ajoc.2022.101528","article-title":"Dupilumab-associated cicatrizing ocular disease","volume":"26","author":"Reddy","year":"2022","journal-title":"Am J Ophthalmol Case Rep"},{"key":"R40-20240828","first-page":"275","article-title":"Dupilumab induced limbal stem cell deficiency","volume":"14","author":"Mehta","year":"2021","journal-title":"Int Med Case Rep J"},{"key":"R41-20240828","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1097\/ICO.0000000000002262","article-title":"Dupilumab-associated conjunctivitis in patients with atopic dermatitis","volume":"39","author":"Liberman","year":"2020","journal-title":"Cornea"},{"key":"R42-20240828","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1001\/jamadermatol.2018.3427","article-title":"cicatrizing blepharoconjunctivitis occurring during dupilumab treatment and a proposed algorithm for its management","volume":"154","author":"Levine","year":"2018","journal-title":"JAMA Dermatol"},{"key":"R43-20240828","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jaip.2022.09.021","article-title":"Impact of a decade of research into atopic dermatitis","volume":"11","author":"Arkwright","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"(1_suppl)","key":"R44-20240828","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1177\/1120672120964756","article-title":"A novel case of ocular cicatricial pemphigoid induced by levamisole-adulterated cocaine","volume":"31","author":"Igwe","year":"2021","journal-title":"Eur J Ophthalmol"},{"key":"R45-20240828","doi-asserted-by":"crossref","first-page":"j4307","DOI":"10.1136\/bmj.j4307","article-title":"Efficacy of recommended drugs against soil transmitted helminths:systematic review and network meta-analysis","volume":"358","author":"Moser","year":"2017","journal-title":"BMJ"},{"key":"R46-20240828","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ad.2022.09.018","article-title":"Cutaneous and mucosal conditions associated with cocaine use","volume":"114","author":"Sanchez-Puigdollers","year":"2023","journal-title":"Actas Dermosifiliogr"},{"key":"R47-20240828","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1097\/DAD.0000000000001837","article-title":"Recurrent antineutrophil cytoplasmic antibody-associated vasculitis induced by levamisole-adulterated cocaine","volume":"43","author":"Macias Alonso","year":"2021","journal-title":"Am J Dermatopathol"},{"key":"R48-20240828","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1590\/abd1806-4841.20175070","article-title":"Identifying the incidence of rash, Stevens-Johnson syndrome and toxic epidermal necrolysis in patients taking lamotrigine:A systematic review of 122 randomized controlled trials","volume":"92","author":"Bloom","year":"2017","journal-title":"An Bras Dermatol"},{"key":"R49-20240828","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1016\/j.genhosppsych.2010.07.010","article-title":"Lamotrigine-induced conjunctivitis","volume":"33","author":"Praharaj","year":"2011","journal-title":"Gen Hosp Psychiatry"},{"key":"R50-20240828","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1046\/j.1442-9071.2003.00717.x","article-title":"Visual loss in a patient with lamotrigine-induced cicatrizing conjunctivitis","volume":"31","author":"McDonald","year":"2003","journal-title":"Clin Exp Ophthalmol"},{"key":"R51-20240828","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1136\/bjo.2006.099085","article-title":"Drug-induced cicatrising granulomatous conjunctivitis","volume":"91","author":"Kahana","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"R52-20240828","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jtos.2022.02.004","article-title":"Drug induced cicatrizing conjunctivitis:A case series with review of etiopathogenesis, diagnosis and management","volume":"24","author":"Singh","year":"2022","journal-title":"Ocul Surf"},{"key":"R53-20240828","doi-asserted-by":"crossref","first-page":"P41","DOI":"10.1016\/j.ophtha.2015.10.053","article-title":"Primary open-angle glaucoma preferred practice PatIn((R)) guidelines","volume":"123","author":"Prum","year":"2016","journal-title":"Ophthalmology"},{"key":"R54-20240828","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1097\/ICO.0b013e3181c325b2","article-title":"Prevalence of ocular surface complaints in patients with glaucoma using topical intraocular pressure-lowering medications","volume":"29","author":"Fechtner","year":"2010","journal-title":"Cornea"},{"key":"R55-20240828","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.jtos.2018.03.002","article-title":"Exploring topical anti-glaucoma medication effects on the ocular surface in the context of the current understanding of dry eye","volume":"16","author":"Wong","year":"2018","journal-title":"Ocul Surf"},{"key":"R56-20240828","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1097\/ICU.0b013e32835c8aba","article-title":"Glaucoma therapy and ocular surface disease:Current literature and recommendations","volume":"24","author":"Anwar","year":"2013","journal-title":"Curr Opin Ophthalmol"},{"key":"R57-20240828","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1089\/jop.2016.0117","article-title":"Use of topical cannabinomimetic palmitoylethanolamide in ocular surface disease associated with antiglaucoma medications","volume":"33","author":"Di Zazzo","year":"2017","journal-title":"J Ocul Pharmacol Ther"},{"key":"R58-20240828","doi-asserted-by":"crossref","first-page":"391","DOI":"10.3109\/02713683.2011.562340","article-title":"Ocular surface disease in patients with ocular hypertension and glaucoma","volume":"36","author":"Stewart","year":"2011","journal-title":"Curr Eye Res"},{"key":"R59-20240828","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.preteyeres.2010.03.001","article-title":"Preservatives in eyedrops:The good, the bad and the ugly","volume":"29","author":"Baudouin","year":"2010","journal-title":"Prog Retin Eye Res"},{"key":"R60-20240828","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1001\/archopht.1994.01090230060021","article-title":"Adverse effects of topical antiglaucoma medication. II. The outcome of filtration surgery","volume":"112","author":"Broadway","year":"1994","journal-title":"Arch Ophthalmol"},{"key":"R61-20240828","doi-asserted-by":"crossref","first-page":"820","DOI":"10.4103\/ijo.IJO_1897_21","article-title":"Long-term outcomes and risk factors for failure of glaucoma filtering surgery in eyes with vernal keratoconjunctivitis and steroid-induced glaucoma","volume":"70","author":"Senthil","year":"2022","journal-title":"Indian J Ophthalmol"},{"key":"R62-20240828","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1097\/ICO.0000000000002506","article-title":"Effects of Terpinen-4-ol on meibomian gland epithelial cells in vitro","volume":"39","author":"Chen","year":"2020","journal-title":"Cornea"},{"key":"R63-20240828","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.ajo.2010.04.016","article-title":"Association of dyslipidemia in moderate to severe meibomian gland dysfunction","volume":"150","author":"Dao","year":"2010","journal-title":"Am J Ophthalmol"}],"container-title":["Indian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_2782_22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:13:23Z","timestamp":1787166803000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_2782_22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":63,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/ijo.ijo_2782_22","relation":{},"ISSN":["0301-4738","1998-3689"],"issn-type":[{"value":"0301-4738","type":"print"},{"value":"1998-3689","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"2022-10-23","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-17","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}